ImmunityBio (NASDAQ:IBRX - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $30.00 target price on the stock.
Other equities research analysts have also recently issued reports about the company. EF Hutton Acquisition Co. I raised ImmunityBio to a "strong-buy" rating in a research report on Wednesday, October 23rd. BTIG Research started coverage on shares of ImmunityBio in a report on Friday, January 10th. They set a "buy" rating and a $6.00 price target on the stock.
Check Out Our Latest Report on IBRX
NASDAQ IBRX traded up $0.05 during mid-day trading on Monday, reaching $3.22. The stock had a trading volume of 879,528 shares, compared to its average volume of 6,170,517. The stock has a market cap of $2.24 billion, a PE ratio of -3.54 and a beta of 0.86. ImmunityBio has a 1 year low of $2.28 and a 1 year high of $10.53. The company has a fifty day moving average price of $3.51 and a 200 day moving average price of $4.08.
A number of hedge funds have recently bought and sold shares of IBRX. China Universal Asset Management Co. Ltd. lifted its stake in shares of ImmunityBio by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 147,754 shares of the company's stock worth $378,000 after purchasing an additional 13,788 shares during the period. Mutual Advisors LLC bought a new stake in shares of ImmunityBio during the 4th quarter valued at $41,000. Virtu Financial LLC purchased a new stake in shares of ImmunityBio in the 3rd quarter worth $51,000. Barclays PLC raised its holdings in ImmunityBio by 127.4% in the 3rd quarter. Barclays PLC now owns 361,036 shares of the company's stock worth $1,344,000 after purchasing an additional 202,248 shares during the period. Finally, XTX Topco Ltd grew its holdings in ImmunityBio by 309.4% during the third quarter. XTX Topco Ltd now owns 92,910 shares of the company's stock valued at $346,000 after purchasing an additional 70,215 shares during the period. Hedge funds and other institutional investors own 8.58% of the company's stock.
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.